A recent phase 2 safety and efficacy study of an anti-interleukin-17A monoclonal antibody for the treatment of giant cell arteritis patients suggests there may soon be another alternative to ...
Coping with steroid-toxicity has become an integral part of the treatment experience for patients with inflammatory disease for more than 70 years. With the development of new immunomodulatory ...
In October 2021, the US Food and Drug Administration issued its first new drug approval for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in a decade. The first-in-class ...